Senores Pharmaceuticals Achieves Strong Financial and Operational Performance in Q1 FY27

Senores Pharmaceuticals Achieves Strong Financial and Operational Performance in Q1 FY27​

Senores Pharmaceuticals Limited has announced its unaudited financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ended June 30, 2026. The company reported robust growth across its businesses, driven by expanding product portfolios and improved profitability.

The company's consolidated revenue stood at ₹ 180 crore, representing a 36% year-on-year increase (Y-o-Y). EBITDA reached ₹ 54 crore, showing an 87% Y-o-Y rise. Net Profit After Tax (PAT) was reported at ₹ 31 crore, marking a 56% growth over the previous year.

Q1 FY27 Segmental Performance Highlights​

The financial performance across various market segments is detailed below:

Operational and Profitability Improvements​

Senores Pharmaceuticals highlighted consistent growth across its business segments, reporting strong revenue increases in the Regulated Markets (42% Y-o-Y) and Emerging Markets (30% Y-o-Y).

The company reported significant improvement in profitability, with EBITDA growing by 87%. This expansion was attributed to a steady focus on manufacturing and cost efficiency, enabling sustainable margin growth.

In terms of portfolio development, Senores Pharmaceuticals nearly doubled its Regulated Markets portfolio. The company expanded from having 30 approved ANDAs (Application Numbering Documents) as of June 2025 to 58 approved ANDAs as of June 2026, with 23 ANDAs already commercialized.

The Emerging Markets business continues on a steady trajectory, reporting revenue growth of approximately 30% Y-o-Y in Q1 FY27. The EBITDA Margin in the Emerging Markets stood at around 14%, supported by an increasing focus on niche products and streamlined go-to-market strategies.

Strategic Outlook and Manufacturing Expansion​

Mr. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, commented on the quarter's performance, noting that the company delivered a healthy result despite a challenging operating environment. He attributed the strong results in Regulated Markets to continuous product portfolio expansion and differentiated sales channels.

Regarding Emerging Markets, Mr. Shah stated that the business is now cash flow positive and achieving near mid teens EBITDA Margin due to the shift towards niche products.

The addition of the USFDA approved manufacturing plant based in Baroda was highlighted as a significant strategic move. This facility enhances scalability and deepens access to Regulated Markets, facilitating accelerated product launches and improving operating leverage and margins. Production has already ramped up at the Apnar facility, with full scale-up expected over the next 12 to 18 months.

Mr. Shah concluded that Senores Pharmaceuticals is well positioned to sustain its growth momentum in FY27 and beyond, backed by a robust product pipeline, expanded manufacturing capacities, and strengthened R&D infrastructure.

SENORES Stock Price Movement​

Today, Senores Pharmaceuticals Limited shares edged higher to settle at ₹1412, closing after gaining 0.58%. The stock traded within a daily range of ₹1378 and ₹1443.7 on 422,207 shares.